M&A Deal Summary |
|
---|---|
Date | 2010-05-05 |
Target | SenoRx |
Sector | Medical Products |
Buyer(s) | C. R. Bard |
Deal Type | Add-on Acquisition |
Deal Value | 213M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1907 |
Sector | Medical Products |
Employees | 14,900 |
Revenue | 3.7B USD (2016) |
C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.
DEAL STATS | # |
---|---|
Overall | 16 of 23 |
Sector (Medical Products) | 12 of 18 |
Type (Add-on Acquisition) | 15 of 22 |
State (California) | 4 of 6 |
Country (United States) | 15 of 22 |
Year (2010) | 2 of 3 |
Size (of disclosed) | 4 of 14 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-05-05 |
SensoRx
Irvine, California, United States SenoRx markets the EnCor(R) stereotactic-guided and MRI-guided breast biopsy systems, the Gel Mark(R) line of breast tissue markers and the Contura(R) balloon catheter for the treatment of breast cancer. The Company is based in Irvine, California. |
Buy | $200M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-05-17 |
FlowCardia
Sunnyvale, California, United States FlowCardia, Inc. is a medical device company which developed and marketed CROSSERTM, the safest and most effective solution for crossing chronic total occlusions in arteries. |
Buy | $80M |